FDA Grants Toripalimab Fast Track Designation for Mucosal Melanoma
March 11, 2021 | Source: PRNewswire DUBLIN, March 11, 2021 /PRNewswire/ — Alkermes plc (Nasdaq: ALKS) today announced…
Melanoma Research
03/11/2021
FDA Grants Toripalimab Fast Track Designation for Mucosal Melanoma
March 11, 2021 | Source: PRNewswire DUBLIN, March 11, 2021 /PRNewswire/ — Alkermes plc (Nasdaq: ALKS) today announced…
|
|
02/05/2021
Alkermes Announces FDA Orphan Drug Designation for Nemvaleukin Alfa for Treatment of Mucosal Melanoma
March 11, 2021| Source: PRNewswire Alkermes plc (Nasdaq: ALKS) today announced that nemvaleukin alfa (“nemvaleukin”, formerly referred to as…
|
|
01/26/2021
FDA Grants Toripalimab Fast Track Designation for Mucosal Melanoma
January 24, 2021 19:07 ET | Source: Junshi Biosciences Junshi Biosciences (HKEX: 1877; SSE: 688180), an innovation-driven biopharmaceutical…
|
|
01/08/2021
Why Is the Tissue Bank So Important For Melanoma Research?
We answer this question with the help of Mohammed Kashani-Sabet, M.D., the Director, Center for Melanoma Research and Treatment;…
|
01/08/2021
What is Oral Parity, and Why Does it Matter?
We answer this question with the help of a pharmacist at a large oncology practice who wishes to remain…
|
11/24/2020
Immunocore’s Tebentafusp Successfully Activates T Cells Against Uveal Melanoma
Published: Nov 23, 2020 By Mark Terry in BIOSPACE Immunocore, based in Oxfordshire, England, Conshohocken, Pennsylvania and Rockville, Maryland, announced that its Phase…
|
|
06/02/2020
WIM: Emphasizing the Whole Patient and the Whole Physician
By, Vallerie A. Malkin In August of 2017, AIM at Melanoma hosted the inaugural Women in Melanoma Initiative in…
|
01/23/2020
AIM at Melanoma Opens the Fourth Branch of Fresh Frozen Primary Tissue Bank at Robert H. Lurie Comprehensive Cancer Center of Northwestern University
January 23, 2020 (San Rafael, California)… AIM at Melanoma and AIM at Melanoma Research Foundation announce the opening of…
|
|
11/14/2019
AIM at Melanoma Opens The Third Branch of Fresh Frozen Primary Tissue Bank at at the Knight Cancer Institute at Oregon Health & Science University
AIM AT MELANOMA OPENS THIRD BRANCH OF FRESH FROZEN PRIMARY TISSUE BANK AT THE KNIGHT CANCER INSTITUTE AT OREGON…
|
|
09/09/2019
AIM at Melanoma Opens the Second Branch of Fresh Frozen Primary Tissue Bank at Sutter’s California Pacific Medical Center
September 9, 2019 (San Rafael, California) AIM at Melanoma announces the grand opening of the second branch of the International…
|
|
Recent Posts
Dec. 30, 2024
Jimmy Carter: A Life that Shaped Cancer Treatment and Hope for Melanoma Patients
Dec. 27, 2024
Bristol Myers Squibb Announces Approval for Subcutaneous Nivolumab
Dec. 12, 2024
Navigating Melanoma Together: 2024 Podcast Wrap-Up
Dec. 10, 2024
Beyond the Clinic’s New Host: Introducing Dr. Sam Siegel
Dec. 09, 2024